Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
|Third Quarter 2017 Press Release|
|Third Quarter 2017 10Q|
OBLN (Common Stock) $7.46 - 0.08 (1.06%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Obalon Announces Upcoming Conference Presentations
Obalon Announces Third Quarter 2017 Financial Results
Obalon Therapeutics, Inc. and Sono Bello Announce Agreement to Offer Novel Weight Loss Treatment in Sono Bello Centers
Obalon Schedules Third Quarter 2017 Financial Results Conference Call for November 3, 2017 at 8:30 a.m. Eastern Time
|There are currently no events scheduled.|